Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3878130 | 0.92 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3885218 | 0.86 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3874279 | 0.86 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3879577 | 0.86 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3885987 | 0.84 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3876968 | 0.83 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3876335 | 0.83 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3878668 | 0.83 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3876261 | 0.82 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3879294 | 0.82 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | claimed |